The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Ultragenyx Pharmaceutical Inc. (RARE) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.35, or 0.89%, to $39.70. The Ultragenyx Pharmaceutical Inc. has recorded 15,589 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Ultragenyx to Participate at Investor Conferences in November.
Ultragenyx Pharmaceutical Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Ultragenyx Pharmaceutical Inc. is $3.23B. A total of 0.6 million shares were traded on the day, compared to an average of 923.89K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, RARE has seen 1 BUY and 5 SELL insider trades, representing the acquisition of 2,000 and the disposition of 9,133 shares. Over the last 12 months, there were 24 BUYs and 28 SELLs from insiders. Insiders purchased 225,162 shares during that period but sold 96,043.
In the most recent transaction, Kassberg Thomas Richard sold 39,878 shares of RARE for 32.78 per share on Oct 23. After the transaction, the CBO & EVP now owns 246,860 company shares. In a previous transaction on Oct 19, KAKKIS EMIL D sold 47,853 shares at 33.52 per share. RARE shares that President & CEO owns now total 599,743.
Among the insiders who sold shares, Huizenga Theodore Alan disposed of 2,163 shares on Sep 07 at a per-share price of $40.80. This resulted in the SVP, Chief Accounting Officer holding 23,614 shares of RARE after the transaction. In another insider transaction, Harris Erik sold 6,000 shares at $37.96 per share on Sep 05. Company shares held by the EVP & Chief Commercial Officer now total 51,281.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for RARE in the last 3 months, the mean price target is $90.00 with high estimates of $140.00 and low estimates of $43.00. In terms of 52-week highs and lows, RARE has a high of $54.98 and a low of $31.52.
As of this writing, RARE has an earnings estimate of -$1.62 per share for the current quarter. EPS was calculated based on a consensus of 15 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$2.45. The company reported an EPS of -$2.25 in the last quarter, which was -8.70% lower than expectations of -$2.07.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RARE’s latest balance sheet shows that the firm has $999.13M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $0.44, while its Total Shareholder’s Equity was $922.56M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.76.